These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29753698)

  • 21. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What is the role of apheresis technology in stem cell transplantation?
    Kiki I
    Transfus Apher Sci; 2017 Dec; 56(6):788-794. PubMed ID: 29162394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.
    Craddock CF
    Bone Marrow Transplant; 2008 Mar; 41(5):415-23. PubMed ID: 18209726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
    Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Safety and effectiveness of tumor-ablative chemotherapy combined with low intensity modified conditioning regimen for 30 patients with hematologic malignancies receiving allogeneic hematopoietic stem cell transplantation].
    Luo RM; Da WM; Hu B; Si YJ; Zhang XM; Du ZL; Liu QH; Wang Y; Yue Y; Chen W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1047-52. PubMed ID: 25130826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis.
    Ustun C; Gotlib J; Popat U; Artz A; Litzow M; Reiter A; Nakamura R; Kluin-Nelemans HC; Verstovsek S; Gajewski J; Perales MA; George T; Shore T; Sperr W; Saber W; Kota V; Yavuz AS; Pullarkat V; Rogosheske J; Hogan W; Van Besien K; Hagglund H; Damaj G; Arock M; Horny HP; Metcalfe DD; Deeg HJ; Devine S; Weisdorf D; Akin C; Valent P
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1348-1356. PubMed ID: 27131865
    [No Abstract]   [Full Text] [Related]  

  • 27. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.
    Nair AP; Barnett MJ; Broady RC; Hogge DE; Song KW; Toze CL; Nantel SH; Power MM; Sutherland HJ; Nevill TJ; Abou Mourad Y; Narayanan S; Gerrie AS; Forrest DL
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1437-44. PubMed ID: 25865648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.
    Smith E; Devlin SM; Kosuri S; Orlando E; Landau H; Lesokhin AM; Chung DJ; Hassoun H; Lendvai N; Landgren O; Giralt S; Chari A; Jagannath S; Koehne G
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):258-267. PubMed ID: 26325439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantation.
    Hobbs GS; Kaur N; Hilden P; Ponce D; Cho C; Castro-Malaspina HR; Giralt S; Goldberg JD; Jakubowski AA; Papadopoulos EB; Sauter C; Koehne G; Yahalom J; Delvin S; Barker JN; Perales MA
    Bone Marrow Transplant; 2016 Jul; 51(7):1010-2. PubMed ID: 26974271
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Leukemia.
    Inagaki J; Noguchi M; Kurauchi K; Tanioka S; Fukano R; Okamura J
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):300-306. PubMed ID: 26371373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation.
    Jones CV; Copelan EA
    Future Oncol; 2009 May; 5(4):559-68. PubMed ID: 19450182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lineage-specific chimerism monitoring after allogeneic haematopoietic stem cell transplantation: do we really know what we are measuring?
    Watson MB; Clouston HJ; Snowden JA; Wilson G; Durkie M; Ward R; Kaur H; Travis D; Barnett D
    Br J Haematol; 2017 Jan; 176(1):139-141. PubMed ID: 26848116
    [No Abstract]   [Full Text] [Related]  

  • 34. Complete donor chimerism following 0/10 HLA-mismatched unrelated donor allogeneic hematopoietic stem cell transplantation.
    Sørensen CD; Møller BK; Olesen G; Hokland P; Hokland M
    Bone Marrow Transplant; 2018 Dec; 53(12):1578-1582. PubMed ID: 29884849
    [No Abstract]   [Full Text] [Related]  

  • 35. Getting fit for allogeneic hematopoietic cell transplantation.
    Wood WA
    Bone Marrow Transplant; 2014 Oct; 49(10):1249-50. PubMed ID: 25068428
    [No Abstract]   [Full Text] [Related]  

  • 36. Allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: a retrospective single-center study.
    Kamranzadeh Fumani H; Zokaasadi M; Kasaeian A; Alimoghaddam K; Mousavi SA; Bahar B; Vaezi M; Ghavamzadeh A
    Hematol Oncol; 2017 Dec; 35(4):935-938. PubMed ID: 27761934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Role of Age in Neurocognitive Functioning among Adult Allogeneic Hematopoietic Cell Transplant Recipients.
    Hoogland AI; Nelson AM; Small BJ; Hyland KA; Gonzalez BD; Booth-Jones M; Anasetti C; Jacobsen PB; Jim HSL
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1974-1979. PubMed ID: 28797784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic transplantation for ALL in adults.
    Stein A; Forman SJ
    Bone Marrow Transplant; 2008 Mar; 41(5):439-46. PubMed ID: 18334992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis.
    Gupta V; Kröger N; Aschan J; Xu W; Leber B; Dalley C; Sabloff M; Lipton JH; Messner H; Brune M
    Bone Marrow Transplant; 2009 Sep; 44(5):317-20. PubMed ID: 19234505
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.